Coalition Against Socialized Medicine Urges the Senate to Reject Including the “Most Favored Nation” (MFN) Policy in Budget Reconciliation Package.

ALEXANDRIA, VA, June 6, 2025 – The Coalition Against Socialized Medicine (CASM), a broad coalition of leading conservative groups, has issued the following statement expressing deep concerns about the possible inclusion of a Most Favored Nation pricing model in the Senate budget reconciliation package.

“The Coalition Against Socialized Medicine (CASM) is deeply concerned about the possible inclusion of a Most Favored Nation (MFN) pricing model in the Senate’s budget reconciliation package. As a coalition of free-market organizations, we recognize the importance of incentivizing innovation in the United States. As CASM has consistently said, regardless of who is in power, MFN actively undermines this by essentially importing foreign price controls by indexing U.S. prices to those in other countries.

“America has long been the global leader in pharmaceutical innovation. We cannot afford to jeopardize this position, especially given recent reports about how China has outpaced the U.S. in clinical trials. The Biden administration’s flawed Inflation Reduction Act (IRA) has already caused significant damage to our healthcare system, particularly Medicare. Congress must do everything in its power to protect American patients and maintain our competitive edge in research and life science.

“Our coalition and several other partner organizations have been vocal critics of the potential inclusion of MFN in reconciliation, raising our concerns across multiple channels. Our message remains clear: price controls are not conservative policy and will not address foreign freeloading; they will only gut America’s medical innovation sector.

“We respectfully urge the Senate to consider these serious consequences carefully and prioritize drug pricing solutions that will put America first, such as requiring other countries to pay their fair share, rooting out the waste, fraud, and abuse driving up Medicaid and Medicare spending, and reining in Pharmacy Benefit Managers (PBMs). Otherwise, American patients could end up paying the consequences.”